HANOI, Vietnam, March 11, 2025 /PRNewswire/ — Vietnam’s esports industry is experiencing unprecedented growth, and with the involvement of national TV stepping into the arena, the country is making a bold statement: Esports is no longer a niche, but a mainstream industry with government backing.

Leading this movement is ON Live Esports (OLE) by Vietnam Television Cable (VTVCab), which has rapidly become Vietnam’s leading esports organizer, distributor and broadcaster. With strong government support and strategic partnerships with global industry leaders like Riot Games, SOOP, VNGGames, Garena, and VIRESA, Vietnam is emerging as a global esports powerhouse.

Unlike many countries where esports struggles for recognition, Vietnam’s government actively supports it as part of its digital economy strategy, accelerating investment, policies, and infrastructure. This backing has allowed pioneers like OLE to drive the industry forward.

“Broadcasting the National Championship of League of Legends, Valorant & Arena of Valor on VTVcab platforms. OLE aims to become a leading entity in owning, organizing, producing, and broadcasting top-tier esports tournaments” – The Vietnamese Government.

As Vietnam’s top owner, producer, and distributor of esports broadcasting rights, OLE has expanded esports access through major international partnerships. VTVcab’s support, OLE has forged strong partnerships with international industry companies such as Riot Games and SOOP, growing its reach.

In 2025, OLE became the title sponsor of Vietnam’s premier League of Legends tournament. Now rebranded as the ON Live Vietnam Championship Series 2025, marking a major milestone in the collaboration of television broadcasting and esports. Organized by the Vietnam Recreational and Electronic Sports Association (VIRESA) and VNGGames, the tournament will commence on February 28, 2025.

VCS has the new title sponsor – OLE by VTVCab.

Besides, OLE has secured an exclusive media rights partnership with Garena, becoming the official distributor for Vietnam’s entire Arena of Valor tournament system. Not only is OLE a leading distributor of esports content, but it is also actively shaping its future to become Vietnam’s largest owner and producer of esports content. After the success of ON Live Valorant Series (OVS) Season 1, OLE quickly launched Season 2, reaffirming its commitment to expanding Vietnam’s esports ecosystem.

These partnerships are a game-changer, further integrating traditional television with the rapidly evolving esports landscape. OLE is actively bringing esports to television, making esports more accessible to the public than ever before. By expanding its broadcast reach, OLE ensures that esports content reaches the widest possible audience, bridging the gap between digital platforms and mainstream media.

OVS has been to Season 2 with many expectations from the audiences.

With government support, corporate investment, and international partnerships, Vietnam is not just catching up—it is setting new industry standards. As OLE continues its expansion, the world is watching. The question is no longer whether Vietnam will be a major esports player, but how far it will go.

SEOUL, South Korea, March 11, 2025 /PRNewswire/ — STRADVISION, a global leader in AI-powered vision perception technology, proudly announces a new industry milestone, surpassing 3 million units in cumulative commercial production. This achievement cements STRADVISION’s leadership in the automotive AI space and marks a record-breaking year of expansion.

In 2024 alone, 1.67 million vehicles worldwide were equipped with STRADVISION’s cutting-edge SVNet perception software, marking a 59% Year-over-Year (YoY) growth. This milestone not only exceeded the company’s 2024 projections but also underscores the rising industry demand for lightweight, high-efficiency AI-driven vision solutions. This surge in production was largely fueled by the launch of new model lineups from a leading German OEM, solidifying STRADVISION’s role as a key technology enabler in next-generation driver-assist and autonomous vehicle systems.

“Surpassing 3 million units in commercial production is a defining milestone for STRADVISION and a testament to the trust our partners place in our technology,” said Philip Vidal, Chief Business Officer of STRADVISION. “The momentum we built in 2024 propels us into 2025 with a clear mission—to scale aggressively, expand into new markets, and cement STRADVISION as the premier AI perception provider ahead of our next phase of growth.”

With a strong foundation in deep learning-based vision perception, STRADVISION continues to expand its global footprint. As the industry accelerates toward higher levels of automation, STRADVISION remains at the forefront, delivering cutting-edge solutions that enhance safety.

As STRADVISION continues its rapid trajectory, 2025 will be a transformational year marked by strategic expansion and innovation. The company is strengthening its presence in China, Europe, Japan, South Korea, and North America, targeting key OEMs for deeper collaboration and broader market penetration. At the same time, STRADVISION is driving exponential growth in commercial deployments, expanding its footprint across global vehicle platforms. To stay at the forefront of AI-driven automotive vision, the company is enhancing SVNet’s capabilities to support higher levels of automation and next-generation perception solutions. In parallel, STRADVISION is laying the foundation for a potential public offering, focusing on operational scale, revenue growth, and strategic partnerships to position itself as a leader in the industry’s next phase of evolution.

For more information about the groundbreaking technology, SVNet, please visit STRADVISION.

About STRADVISION 

Founded in 2014, STRADVISION is an automotive industry pioneer in artificial intelligence-based vision perception technology for ADAS. The company is accelerating the advent of fully autonomous vehicles by making ADAS features available at a fraction of the market cost compared with competitors. STRADVISION’s SVNet is being deployed on various vehicle models in partnership with OEMs; can power ADAS and autonomous vehicles worldwide; and is serviced by over 300 employees in Seoul, San Jose, Detroit, Tokyo, Shanghai, and Dusseldorf. STRADVISION has been honored with Frost & Sullivan’s 2022 Global Technology Innovation Leadership Award, the Gold Award at the 2022 and 2021 AutoSens Awards for Best-in-Class Software for Perception Systems, and the 2020 Autonomous Vehicle Technology ACES Award in Autonomy (software category). In addition, STRADVISION and its software have achieved TISAX’s AL3 standard for information security management, as well as being certified to the ISO 9001:2015 for Quality Management Systems and ISO 26262 for Automotive Functional Safety. 

SEOUL, South Korea, March 11, 2025 /PRNewswire/ — To mark International Women’s Day which took place on March 8, digital travel platform Agoda unveiled travel insights about South Korean women. The findings revealed that while both men and women plan to travel more in 2025, South Korean women are leading the way in exploring new destinations and prioritizing shared adventures. 

• Exploring New Destinations 

The survey showed that 67% of South Korean women expressed interest in visiting unfamiliar destinations. This figure is higher than the Asia-wide average of 60%, highlighting their strong desire to experience diverse cultures and landscapes. Women in South Korea are venturing beyond familiar travel spots, embracing the joy of exploring new markets firsthand. 

• Preference for Family Travel 

The survey also found that 39% of women preferred traveling with family, while 22% chose to travel with their partners. By creating unforgettable memories with loved ones, women in South Korea are adding deeper meaning to their journeys through shared experiences. 

• Short Travel Experiences 

The majority of South Korean women (52%) showed a preference for short trips lasting 2–5 days. These brief escapes provide an opportunity to immerse themselves in culture and adventure while taking a refreshing break from their busy routines. Short trips have become a popular choice for balancing daily life with the thrill of new experiences. 

Lee Jun-hwan, Country Director, South Korea at Agoda stated, “Our survey reveals that South Korean women are leading changes in travel trends, particularly with their adventurous spirit and focus on meaningful journeys with family. Agoda remains committed to helping women in South Korea explore new destinations with great deals on accommodations, flights and activities.” 

Agoda’s extensive offerings include over 5 million vacation properties, 130,000 flight routes, and 300,000 activities, all bookable in one place. Customers can discover the best deals and plan unforgettable trips by visiting agoda.com/deals or using the Agoda mobile app.  

’15 Years Old Single Malt Whisky’ is Kavalan’s first age statement whisky

TAIPEI, March 11, 2025 /PRNewswire/ — Kavalan Distillery is launching its first-ever whisky with an age statement, matured in four unique casks: ex-Bourbon, Oloroso Sherry, Ruby Port, and Puncheon.

The release marks a milestone in the journey of this Taiwanese distiller, which has broken boundaries not just by region, but now also by time and maturation.

The whisky also pays tribute to the historic moment when Kavalan and Taiwan began whisky making. On this day in 2006, the first ever drops of Taiwanese-made new make spirit rolled off the stills, setting the stage for nearly two decades of innovation and craftsmanship.

Kavalan 15 Years Old Single Malt Whisky 2025 Edition, 43% ABV, 700ml will be released in just 30,000 bottles globally, representing rare stock from the subtropical distillery’s ultra-aged whisky selection.

One of Kavalan’s oldest bottlings, CEO Mr YT Lee said the 2025 edition has been masterfully blended using hand-selected aged whisky reserves, drawing on the four distinct cask types.

“We wanted to achieve extraordinary depth and balance with multiple layers of complexity befitting of a high-age statement whisky. So we created a formula based on a four-cask maturation that would maximise the characteristics of each cask and achieve a rich harmony in the final product,” he said.

A tribute to 15 years of mastery, Kavalan presents this whisky as a timeless classic, capturing the true nature of time and craftsmanship. The packaging design embodies natural wood grain, symbolising the depth and maturity gained through years of ageing. The bottle design reflects the concept of ‘fusion,’ harmoniously vatted from four cask types, with textured oak patterns representing their distinct characteristics. The gold-foiled Kavalan logo adds a touch of luxury and sophistication, perfectly encapsulating the refined depth of this 15-year-old whisky.

The Kavalan 15 Years Old Single Malt Whisky 2025 Edition is available through Kavalan’s official channels in Taiwan, including the Kavalan Distillery Shop, Kavalan Whisky shops, Kavalan Whisky Bar, and select local liquor stores. 

Kavalan 15 Years Old Single Malt Whisky (2025 Edition)

Product Description:

Kavalan 15 Years Old, 700ml 43% ABV whisky is a testament to Kavalan’s craftsmanship, showcasing the perfect balance of ageing, cask influence, and blending artistry in every sip.

Colour: Golden caramel

Nose: Captivating aromas of caramel apple mousse, fresh chocolate, walnut cinnamon rolls, and creamy popcorn, intertwined with subtle hints of dried tangerine peel and plum. The finish reveals the sweetness of toffee and black date fruit, evoking a warm, indulgent sweetness.

Palate: Lush citrus aromas of bergamot, lemon, orange, and grapefruit dance with the sweet whispers of dried cranberries, raisins, and longan, unfolding into velvety notes of dark chocolate gelato and caramel walnut coffee mousse. The finish lingers with the comforting warmth of woody cinnamon spice.

About Kavalan Whisky

Kavalan Distillery in Yilan County has been pioneering the art of single malt whisky in Taiwan since 2005. Our whisky, aged in intense humidity and heat, sources the crystal meltwaters of Snow Mountain and is enhanced by sea and mountain breezes. These conditions combine to create Kavalan’s signature creaminess. Taking Yilan County’s old name, our distillery is backed by about 45 years of beverage-making under parent company, King Car Group. We have collected 900 gold awards or higher from the industry’s most competitive contests.

Contact:
Kaitlyn Tsai
kaitlyn@kingcar.com.tw 

Britney Chen
britneychen@kingcar.com.tw 

New studies reveal that the three-strain Bacillus probiotic can better protect weaned piglets against diverse health challenges.

SINGAPORE, March 11, 2025 /PRNewswire/ — IFF (NYSE:IFF) today announced the extension of their three-strain Bacillus probiotic, Enviva^® PRO, to pigs. By incorporating IFF’s probiotic into their diet, producers will be better positioned to protect their animals against diverse health challenges. The extension of Enviva^® PRO enhances IFF’s robust portfolio of proven, cost-effective animal nutrition and health solutions that help customers optimize production, livability and profitability.

“The weaning and post-weaning period can be extremely difficult to navigate for swine producers, so implementing a nutritional management strategy is crucial for improving their welfare and avoiding growth setbacks,” said Dr. Ester Vinyeta, swine innovation lead at IFF. “In addition to the proven benefits of Enviva^® PRO already experienced by broiler producers, swine producers now can have peace of mind that their litters have optimal gut health – helping them meet growing production demands.”

Post-weaning, piglets may face challenges like nutritional stress, reduced feed intake, and digestive health issues, which can impact performance. Enviva^® PRO is proven to establish and maintain a favorable nutribiotic state that supports optimal gut function, leading to improved nutrient digestion and performance. Extensive studies performed by IFF found that compared to the control group, Enviva^® PRO improved average daily weight gain by 2.5% and reduced diarrhea frequency by 6.3%.

Enviva^® PRO is currently available to swine producers across Japan and the US. IFF plans to extend availability to other territories following pending regulatory authorizations.

Learn more about the benefits of Enviva^® PRO and nutribiosis in animal production at animalnutrition.iff.com/enviva-pro.

About Danisco Animal Nutrition & Health

Danisco Animal Nutrition & Health, part of IFF, is an industry leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, essential oils and probiotics. Through the lens of nutribiosis, IFF invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. Danisco Animal Nutrition & Health capabilities are underpinned by the quality and quantity of our trials, including over 100,000 guts sampled from over 600 farms, investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit iff.com/animal-nutrition.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ^SM or ^® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

TOKYO, March 11, 2025 /PRNewswire/ — Eviden, the Atos Group business leading in digital, cloud, big data and security today announces the launch of Evidian Orbion, its next-generation Identity-as-a-Service (IDaaS) solution. Evidian Orbion integrates Identity Governance and Administration (IGA), Access Management (AM), and Privileged Access Management (PAM) into a single as-a-Service solution designed for hybrid environments. Evidian Orbion offers organizations a flexible, scalable way to manage identities and access rights, with a focus on efficiency and security.

Securing the extended enterprise 

For several years, companies had structured themselves around an internal security perimeter, protected by firewalls and VPNs. Today, employees and third-party partners need to access business applications, that may run outside of companies’ internal perimeter, from a variety of locations outside the company’s internal network. This identity-first security paradigm introduces a new level of complexity for identity and access management. Evidian Orbion focuses on reducing IAM deployment complexity and strengthens deployments with capacities like self-enrolment and integration with Identity Proofing tools. Evidian Orbion is built to scale for mid-market and large organizations.

Meeting enhanced regulatory and sovereignty requirements  

What’s more, the regulatory landscape like the European NIS 2 Directive, for example, extends security requirements, requiring companies to further formalize their risk analysis policies, speed up the processing and disclosure of vulnerabilities, improve the handling of security incidents, define access control policies, and deploy strong authentication. Evidian Orbion offers a secure and compliant IAM foundation, for governing access controls and implementing multi-factor authentication. The solution provides advanced capabilities like identity proofing, decentralized identities (SSI), and a highly secure infrastructure designed with DevSecOps.  

David Leporini, Director of IAM Cybersecurity Products & General Manager of Evidian, Eviden, Atos Group, said: “Evidian Orbion simplifies IAM management by offering a cloud-native solution that reduces complexity and overhead for enterprises. In addition, the solution also provides essential IAM functionalities such as identity governance and access management, all in a scalable and flexible SaaS model. With Orbion, enterprises can manage identities across applications securely, ensuring compliance while seamlessly scaling to meet evolving business needs.” 

Martin Kuppinger, Principal Analyst & Co-founder, KuppingerCole Research said: “Evidian Orbion is a powerful solution in the Identity Fabrics market segment. With its deployment model, it is targeted at mid-market and large organizations, providing them the flexibility they need. Also, with Evidian being a European vendor and IDaaS deployment from EU data centers, the solution is well positioned for serving the needs of EU-based organizations that mandate or prefer sovereign solutions with EU data residency, such as governmental agencies and critical infrastructure companies.”

For more information about Evidian Orbion, please visit: https://www.evidian.com/products/orbion-identity-and-access-management-as-a- service-iam/

About Eviden¹ 

Eviden is a next-gen technology leader in data-driven, trusted and sustainable digital transformation with a strong portfolio of patented technologies. With worldwide leading positions in advanced computing, security, AI, cloud and digital platforms, it provides deep expertise for all industries in more than 47 countries. Bringing together 41,000 world-class talents, Eviden expands the possibilities of data and technology across the digital continuum, now and for generations to come. Eviden is an Atos Group company with an annual revenue of c. € 5 billion. 

About Atos

Atos is a global leader in digital transformation with c. 82,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris. 

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. 

1 Eviden business is operated through the following brands: AppCentrica, ATHEA, Cloudamize, Cloudreach, Cryptovision, DataSentics, Edifixio, Engage ESM, Evidian, Forensik, IDEAL GRP, In Fidem, Ipsotek, Maven Wave, Profit4SF, SEC Consult, Visual BI, X-Perion. Eviden is a registered trademark. © Eviden SAS, 2025. 

Logo: https://laotiantimes.com/wp-content/uploads/2025/03/eviden_logo.jpg

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Michael D. Patten as Chief Strategy Officer. Michael will be based in the United States and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

In this role, Michael will be responsible for formulating and overseeing the global corporate development and growth strategy for Harbour BioMed. In addition, as the Head of Global Alliance, he will lead efforts to manage and strengthen Harbour BioMed’s global strategic partner network and ecosystem, with a particular focus on high-potential markets outside of China, further enhancing Harbour BioMed’s global branding and presence.

Michael brings extensive experience and a strong track record in the biopharmaceutical industry. During his tenure at Bristol Myers Squibb, he held several key leadership roles. Most recently, as Head of Equity & Venture Capital, he led and managed significant numbers of strategic equity investments and LP commitments across the life science ecosystem. Prior, he held roles of increasing seniority in Business Development and Alliance Leadership, successfully executing transactions and managing multiple early- and late-stage business development alliances, demonstrating exceptional expertise in business development and alliance management.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are pleased to welcome Michael D. Patten as our Chief Strategy Officer. Harbour BioMed has always been committed to the discovery, development and commercialization of innovative biotherapeutics, striving to provide more effective treatment options to patients. Michael’s academic background and extensive experience align perfectly with our strategic direction. I am confident that with Michael’s expertise, we will further expand our global footprint and enhance the visibility and impact of Harbour BioMed.”

Michael D. Patten, Chief Strategy Officer of Harbour BioMed, added: “I am excited to join Harbour BioMed at such a pivotal time. The company’s innovative platforms and commitment to addressing unmet medical needs create tremendous potential. I look forward to driving strategic initiatives with existing and new partners that will accelerate growth globally and deliver impactful therapies to patients.”

Michael holds a Bachelor of Science with Joint Honors in Pharmacology & Business Studies from the University of Edinburgh, a Master of Science in Pharmaceutical Medicine from the University of Surrey, and an MBA from the University of Maastricht (EuroMBA Consortium).

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The proprietary antibody technology platform Harbour Mice^® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^®, and HBICE^® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com. 

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Dr. Ian Y. Liu as Senior Vice President, Global Head of Legal. Dr. Liu will be based in the U.S. and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

With his extensive legal expertise and industry experience, Dr. Liu will oversee business development transactions, ensuring legal and regulatory compliance while facilitating seamless execution to safeguard the company’s interests. He will also lead the company’s global intellectual property strategy. Additionally, Dr. Liu will take full responsibility for managing U.S.-related legal affairs, including prosecution and litigation of all legal cases, protecting the company’s business operations in the region and supporting its strategic growth in the U.S. market.

Before joining Harbour BioMed, Dr. Liu worked at renowned law firms, including Finnigan, Henderson, Farabow, Garrett & Dunner, LLP, and K&L Gates, LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he held key positions such as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, demonstrating exceptional ability in handling complex legal matters and commercial negotiations.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: ” We are pleased to welcome Dr. Ian Y. Liu to Harbour BioMed. As we continue to expand our business globally, Dr. Liu’s expertise in intellectual property, business transactions, and regulatory affairs will be invaluable. With his extensive legal expertise and industry experience, we look forward to him playing a critical role in supporting the company’s sustained growth in the U.S. and international markets, further strengthening our industry position and global impact.”

Dr. Ian Y. Liu, Senior Vice President, Global Head of Legal of Harbour BioMed, added: “Harbour BioMed has always been at the forefront of drug discovery and development, business innovation, and globalization. It is a privilege and honor to become a member of Harbour BioMed and I am looking forward to contributing to Harbour BioMed’s bright future.”   

Dr. Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The proprietary antibody technology platform Harbour Mice^® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^®, and HBICE^® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.